FOXO Technologies Inc. announced that the United States Patent & Trademark Office (USPTO) has provided an Issue Notification for a key patent utilizing a machine learning model trained to determine a biochemical state and/or medical condition using DNA epigenetic data to enable the commercialization of epigenetic biomarkers. Previously, the USPTO had issued Notices of Allowance to the Company for two related patents and the Company awaits Issue Notification for the second allowed patent. The first patent, for which the Company has received an Issue Notification, aids in practical applications of the technology that include generating epigenetic biomarkers.

On occasion, epigenetic data may be missing or unreliable because a specific DNA site may not have been assayed or was unreliably measured. The patent allows the use of machine learning estimators to ?fill in? the missing or unreliable epigenetic values at specific loci.

The second patent, for which the Company received a Notice of Allowance, leverages machine learning to estimate aspects about an individual?s health, such as disease states, biomarker levels, drug use, health histories, and factors used to underwrite mortality risk. Commercial applications for this patent may include a potential AI platform for the delivery of health and well-being data-driven insights to individuals, healthcare professionals and third-party service providers, life insurance underwriting, clinical testing, and consumer health. To support these patents, the Company has generated epigenetic data for over 13,000 individuals through internally sponsored research and external research collaborations.

Pairing these data with broad phenotypic information is expected to help drive product development as demonstrated in the Company?s patent claims.